Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Mild To Moderate Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Mild To Moderate Plaque Psoriasis: Overview
Psoriasis is a genetically determined, systemic, immune-mediated long-term inflammatory condition that affects the skin, nails and joints. When psoriasis affects more than 5 percent of your body, it’s considered moderate to severe. It may affect your genitals, face, hands, and feet. Biologic drugs are a popular treatment option for this type of psoriasis. Biologics may be used alone or with other treatments to ease your psoriasis. The doctor may assess the severity by looking at the physical symptoms of psoriasis. They may look for erythema (redness), scaling, and induration (lesion thickness). These three signs are often used to classify the severity of psoriasis.
“Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mild To Moderate Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Mild To Moderate Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Mild To Moderate Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mild To Moderate Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Mild To Moderate Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mild To Moderate Plaque Psoriasis.
Mild To Moderate Plaque Psoriasis Emerging Drugs Chapters
This segment of the Mild To Moderate Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mild To Moderate Plaque Psoriasis Emerging Drugs
Roflumilast topical: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis. The drug is currently in phase 3 of clinical trials for the treatment of mild to moderate psoriasis.
CC-90006: AnaptysBio
AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.
Further product details are provided in the report……..
Mild To Moderate Plaque Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Mild To Moderate Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Mild To Moderate Plaque Psoriasis
There are approx. 4+ key companies which are developing the therapies for Mild To Moderate Plaque Psoriasis. The companies which have their Mild To Moderate Plaque Psoriasis drug candidates in the most advanced stage, i.e. phase III include, Acrutis Biotherapeutics Biopharma.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Mild To Moderate Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Mild To Moderate Plaque Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mild To Moderate Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mild To Moderate Plaque Psoriasis drugs.
Mild To Moderate Plaque Psoriasis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Mild To Moderate Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Mild To Moderate Plaque Psoriasis: Overview
Psoriasis is a genetically determined, systemic, immune-mediated long-term inflammatory condition that affects the skin, nails and joints. When psoriasis affects more than 5 percent of your body, it’s considered moderate to severe. It may affect your genitals, face, hands, and feet. Biologic drugs are a popular treatment option for this type of psoriasis. Biologics may be used alone or with other treatments to ease your psoriasis. The doctor may assess the severity by looking at the physical symptoms of psoriasis. They may look for erythema (redness), scaling, and induration (lesion thickness). These three signs are often used to classify the severity of psoriasis.
“Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mild To Moderate Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Mild To Moderate Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Mild To Moderate Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mild To Moderate Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Mild To Moderate Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mild To Moderate Plaque Psoriasis.
Mild To Moderate Plaque Psoriasis Emerging Drugs Chapters
This segment of the Mild To Moderate Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mild To Moderate Plaque Psoriasis Emerging Drugs
Roflumilast topical: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis. The drug is currently in phase 3 of clinical trials for the treatment of mild to moderate psoriasis.
CC-90006: AnaptysBio
AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.
Further product details are provided in the report……..
Mild To Moderate Plaque Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Mild To Moderate Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Mild To Moderate Plaque Psoriasis
There are approx. 4+ key companies which are developing the therapies for Mild To Moderate Plaque Psoriasis. The companies which have their Mild To Moderate Plaque Psoriasis drug candidates in the most advanced stage, i.e. phase III include, Acrutis Biotherapeutics Biopharma.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Mild To Moderate Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Mild To Moderate Plaque Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mild To Moderate Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mild To Moderate Plaque Psoriasis drugs.
Mild To Moderate Plaque Psoriasis Report Insights
- Mild To Moderate Plaque Psoriasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Mild To Moderate Plaque Psoriasis drugs?
- How many Mild To Moderate Plaque Psoriasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mild To Moderate Plaque Psoriasis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mild To Moderate Plaque Psoriasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mild To Moderate Plaque Psoriasis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Acrutis Biotherapeutics
- AnaptysBio
- Evelo Biosciences
- Roflumilast topical
- CC-90006
- EDP1815
Introduction
Executive Summary
Mild To Moderate Plaque Psoriasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mild To Moderate Plaque Psoriasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Mild To Moderate Plaque Psoriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Mild To Moderate Plaque Psoriasis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Roflumilast topical: Acrutis Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CC-90006: AnaptysBio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Mild To Moderate Plaque Psoriasis Key Companies
Mild To Moderate Plaque Psoriasis Key Products
Mild To Moderate Plaque Psoriasis- Unmet Needs
Mild To Moderate Plaque Psoriasis- Market Drivers and Barriers
Mild To Moderate Plaque Psoriasis- Future Perspectives and Conclusion
Mild To Moderate Plaque Psoriasis Analyst Views
Mild To Moderate Plaque Psoriasis Key Companies
Appendix
Executive Summary
Mild To Moderate Plaque Psoriasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mild To Moderate Plaque Psoriasis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Mild To Moderate Plaque Psoriasis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Mild To Moderate Plaque Psoriasis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Roflumilast topical: Acrutis Biotherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
CC-90006: AnaptysBio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Mild To Moderate Plaque Psoriasis Key Companies
Mild To Moderate Plaque Psoriasis Key Products
Mild To Moderate Plaque Psoriasis- Unmet Needs
Mild To Moderate Plaque Psoriasis- Market Drivers and Barriers
Mild To Moderate Plaque Psoriasis- Future Perspectives and Conclusion
Mild To Moderate Plaque Psoriasis Analyst Views
Mild To Moderate Plaque Psoriasis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Mild To Moderate Plaque Psoriasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Mild To Moderate Plaque Psoriasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Mild To Moderate Plaque Psoriasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Mild To Moderate Plaque Psoriasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
